

# EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

**No.** CE 699273  
**Issued To:** **Braile Biomédica Indústria, Comércio e Representações Ltda.**  
**Av. Pres. Juscelino Kubitschek de Oliveira, 1505**  
**Jardim Tarraf**  
**São José do Rio Preto**  
**São Paulo**  
**15091-450**  
**Brasil**

In respect of:

**Design, development and manufacture of sterile Cardiopulmonary Bypass Kits and Components including Membrane Oxygenators, Tubes and Blood Reservoirs.**

on the basis of our examination of the quality assurance system under the requirements of Council Directive 93/42/EEC, Annex II excluding section 4. The quality assurance system meets the requirements of the directive. For the placing on the market of class III products an Annex II section 4 certificate is required.

For and on behalf of BSI, a Notified Body for the above Directive (Notified Body Number 2797):



Gary E Slack, Senior Vice President Medical Devices

First Issued: **2020-10-20**

Date: **2020-10-20**

Expiry Date: **2024-05-26**

...making excellence a habit.™

Page 1 of 2

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.


# EC Certificate - Full Quality Assurance System

## Supplementary Information to CE 699273

Issued To:

**Braile Biomédica Indústria, Comércio e Representações Ltda.**  
**Av. Pres. Juscelino Kubitschek de Oliveira, 1505**  
**Jardim Tarraf**  
**São José do Rio Preto**  
**São Paulo**  
**15091-450**  
**Brasil**

Number	Device Name	Intended purpose per IFU
<b>Class IIa</b>		
MD0102	Cardiopulmonary Bypass kits and components	---



First Issued: **2020-10-20**

Date: **2020-10-20**

Expiry Date: **2024-05-26**

...making excellence a habit.™

Page 2 of 2

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.

Information and Contact: BSI, Say Building, John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands Tel: + 31 20 346 0780

BSI Group The Netherlands B.V. registered in The Netherlands under 33264284.

A member of BSI Group of Companies.

# EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

## List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 699273**  
Date: **2020-10-20**  
Issued To: **Braile Biomédica Indústria, Comércio e Representações Ltda.**  
**Av. Pres. Juscelino Kubitschek de Oliveira, 1505**  
**Jardim Tarraf**  
**São José do Rio Preto**  
**São Paulo**  
**15091-450**  
**Brasil**

<b>Subcontractor:</b>	<b>Service(s) supplied</b>
Mars Medical Landhausstraße 46 Stuttgart 70190 Germany	<b>EU Representative</b>
Oximed - Tecnologia em Esterilização Eireli Rua Ulysses Jamil Cury, 920 Distrito Industrial São José do Rio Preto São Paulo 15092-601 Brazil	<b>ETO Sterilization</b>

...making excellence a habit.™

# EC Certificate - Full Quality Assurance System

## Certificate History

Certificate No: **CE 699273**  
 Date: **2020-10-20**  
 Issued To: **Braile Biomédica Indústria, Comércio e Representações Ltda.**  
**Av. Pres. Juscelino Kubitschek de Oliveira, 1505**  
**Jardim Tarraf**  
**São José do Rio Preto**  
**São Paulo**  
**15091-450**  
**Brasil**

### Certificate History

Date	Reference number	Action
20 October 2020	9645320	First Issue
<b>Non-significant changes approved after the 26<sup>th</sup> May 2021 as per the Transitional Provisions of MDR Article 120.3</b>		
23 December 2021	3563207	The authorized representative changed from Obelis S.A to Mars Medical.

...making excellence a habit.™

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.

23 December 2021

Braile Biomédica Indústria, Comércio e Representações Ltda.  
 Av. Pres. Juscelino Kubitschek de Oliveira, 1505  
 Jardim Tarraf  
 São José do Rio Preto  
 São Paulo  
 15091-450  
 Brasil

To whom it may concern,

The transitional provisions specified in MDR Article 120(3) prohibit Notified Bodies from issuing new certificates or amending, modifying, supplementing any existing MDD/AIMDD certificates from 26<sup>th</sup> May 2021.

This letter is to confirm that BSI has reviewed and approved the change(s) detailed in the table below. These changes do not represent a significant change in design or intended purpose under MDR Article 120(3) and as per the guidance provided in MDCG 2020-3. The related MDD certificate specified below remains valid until the expiry date specified on the certificate.

Certificate	Directive and Annex	Reference Number	Changes approved
CE 699273	93/42/EEC Annex II excluding Section 4	3563207	The authorized representative changed from: Obelis S.A Bd. Général Wahis, 53 1030 Brussels Belgium  to: Mars Medical Landhausstraße 46 70190 Stuttgart Germany

Should you have any queries concerning your certification, or if we can be of further assistance to you, please contact your BSI Scheme Manager.

Yours sincerely,



Gary Slack  
 Senior Vice President, Medical Devices

BSI Group The Netherlands B.V.  
 Say Building  
 John M. Keynesplein 9  
 1066 EP Amsterdam  
 The Netherlands

T: +31 20 346 0780  
 info.nl@bsigroup.com  
 bsigroup.nl

Page 1 of 1



Braille Biomédica Indústria, Comércio e Representações Ltda.  
Av. Pres. Juscelino Kubitschek de Oliveira, 1505  
Jardim Tarraf I  
São José do Rio Preto  
São Paulo  
15091-450  
Brasil

20 May 2024

## Notified Body Confirmation Letter

Reference: **EU2023-607/868744**

To whom it may concern,

### **Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices**

This letter confirms that, **BSI Group The Netherlands B.V.**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number **2797** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Braille Biomédica Indústria, Comércio e Representações Ltda.  
Av. Pres. Juscelino Kubitschek de Oliveira, 1505  
Jardim Tarraf I  
São José do Rio Preto  
São Paulo  
15091-450  
Brasil  
SRN Number: BR-MF-000016583

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an MDR application has been received, written

---

BSI Group The Netherlands B.V.	bsigroup.com
Say Building	bsigroup.nl
John M. Keynesplein 9, 1066 EP	T: +31 20 346 0780
Amsterdam, The Netherlands	

Page 1 of 4

Validity of this letter may be verified by writing to [Certificate.Verification@bsigroup.com](mailto:Certificate.Verification@bsigroup.com)



agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of BSI Group The Netherlands B.V.,



Graeme Tunbridge  
Senior Vice President, Medical Devices

**Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
789871635622276-6Z	Class IIa	N/A	CE 699273; NB #2797
789871635622278-75	Class IIa	N/A	CE 699273; NB #2797
789871635622280-6Q	Class IIa	N/A	CE 699273; NB #2797
789871635622282-6U	Class IIa	N/A	CE 699273; NB #2797
789871635622284-6Y	Class IIa	N/A	CE 699273; NB #2797
789871635622375-74	Class IIa	N/A	CE 699273; NB #2797
789871635622378-7A	Class IIa	N/A	CE 699273; NB #2797
789871635622257-6V	Class IIa	N/A	CE 699273; NB #2797
789871635622261-6L	Class IIa	N/A	CE 699273; NB #2797
789871635622266-6W	Class IIa	N/A	CE 699273; NB #2797
789871635622271-6P	Class IIa	N/A	CE 699273; NB #2797
789871635622381-6X	Class IIa	N/A	CE 699273; NB #2797
789871635622383-73	Class IIa	N/A	CE 699273; NB #2797
78987163510159030111-GD	Class IIa	N/A	CE 699273; NB #2797
789871635622286-74	Class IIa	N/A	CE 699273; NB #2797
789871635622290-6T	Class IIa	N/A	CE 699273; NB #2797
789871635622294-73	Class IIa	N/A	CE 699273; NB #2797
789871635622298-7B	Class IIa	N/A	CE 699273; NB #2797
789871635622302-69	Class IIa	N/A	CE 699273; NB #2797
78987163510159039001-J4	Class IIa	N/A	CE 699273; NB #2797
789871635622258-6X	Class IIa	N/A	CE 699273; NB #2797
789871635622262-6N	Class IIa	N/A	CE 699273; NB #2797
789871635622267-6Y	Class IIa	N/A	CE 699273; NB #2797
789871635622272-6R	Class IIa	N/A	CE 699273; NB #2797
789871635622277-73	Class IIa	N/A	CE 699273; NB #2797
789871635622279-77	Class IIa	N/A	CE 699273; NB #2797



**Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A	N/A	N/A	N/A

**Confirmation Letter Revision History**

Date	Action
2024/05/20	Initial issue

MDF7012